The Platelet Anaphylatoxin Receptor C5aR1 (CD88) Is a Promising Target for Modulating Vessel Growth in Response to Ischemiaa

Henry Nording; Lasse Baron; Antje Lübken; Hossein Emami; Jacob von Esebeck; Moritz Meusel; Christian Sadik; Nancy Schanze; Daniel Duerschmied; Jörg Köhl; Götz Münch; Harald F. Langer

doi:10.1055/a-2156-8048

TH Open, Table of Contents

CC BY 4.0 · TH Open 2023; 07(04): e289-e293
DOI: 10.1055/a-2156-8048

Letter to the Editor

The Platelet Anaphylatoxin Receptor C5aR1 (CD88) Is a Promising Target for Modulating Vessel Growth in Response to Ischemia^a

Henry Nording

¹Cardioimmunology Group, Medical Clinic II, University Heart Center Lübeck, Lübeck, Germany

²DZHK (German Centre for Cardiovascular Research), Partner Site Hamburg/Lübeck/Kiel, Lübeck, Germany

,

Lasse Baron

¹Cardioimmunology Group, Medical Clinic II, University Heart Center Lübeck, Lübeck, Germany

,

Antje Lübken

¹Cardioimmunology Group, Medical Clinic II, University Heart Center Lübeck, Lübeck, Germany

,

Hossein Emami

¹Cardioimmunology Group, Medical Clinic II, University Heart Center Lübeck, Lübeck, Germany

,

Jacob von Esebeck

¹Cardioimmunology Group, Medical Clinic II, University Heart Center Lübeck, Lübeck, Germany

,

Moritz Meusel

³Medical Clinic II, University Hospital, University Heart Center Lübeck, Lübeck, Germany

,

Christian Sadik

⁴Clinic for Dermatology, University of Lübeck, University Hospital, Lübeck, Germany

,

Nancy Schanze

⁵Department of Cardiology, Angiology, Haemostaseology and Medical Intensive Care, University Medical Centre Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany

,

Daniel Duerschmied

⁵Department of Cardiology, Angiology, Haemostaseology and Medical Intensive Care, University Medical Centre Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany

⁶German Centre for Cardiovascular Research (DZHK), Partner Site Heidelberg/Mannheim, Germany

⁷European Center for Angioscience, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany

,

Jörg Köhl

⁸ISEF, University of Lübeck, Lübeck, Germany

,

Götz Münch

⁹AdvanceCOR, Martinsried, Germany

,

Harald F. Langer

¹Cardioimmunology Group, Medical Clinic II, University Heart Center Lübeck, Lübeck, Germany

²DZHK (German Centre for Cardiovascular Research), Partner Site Hamburg/Lübeck/Kiel, Lübeck, Germany

⁴Clinic for Dermatology, University of Lübeck, University Hospital, Lübeck, Germany

⁵Department of Cardiology, Angiology, Haemostaseology and Medical Intensive Care, University Medical Centre Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany

⁶German Centre for Cardiovascular Research (DZHK), Partner Site Heidelberg/Mannheim, Germany

› Author Affiliations

Abstract

Full Text

References

References
1 Roth GA, Johnson C, Abajobir A. et al. Global, regional, and national burden of cardiovascular diseases for 10 causes, 1990 to 2015. J Am Coll Cardiol 2017; 70 (01) 1-25
2 Galkina E, Ley K. Immune and inflammatory mechanisms of atherosclerosis (*). Annu Rev Immunol 2009; 27: 165-197
3 Iyer SR, Annex BH. Therapeutic angiogenesis for peripheral artery disease: lessons learned in translational science. JACC Basic Transl Sci 2017; 2 (05) 503-512
4 Noris M, Remuzzi G. Overview of complement activation and regulation. Semin Nephrol 2013; 33 (06) 479-492
5 Panagiotou A, Trendelenburg M, Osthoff M. The lectin pathway of complement in myocardial ischemia/reperfusion injury-review of its significance and the potential impact of therapeutic interference by C1 esterase inhibitor. Front Immunol 2018; 9: 1151
6 Yin W, Ghebrehiwet B, Weksler B, Peerschke EI. Classical pathway complement activation on human endothelial cells. Mol Immunol 2007; 44 (09) 2228-2234
7 Ghebrehiwet B, CebadaMora C, Tantral L, Jesty J, Peerschke EI. gC1qR/p33 serves as a molecular bridge between the complement and contact activation systems and is an important catalyst in inflammation. Adv Exp Med Biol 2006; 586: 95-105
8 Markiewski MM, Daugherity E, Reese B, Karbowniczek M. The role of complement in angiogenesis. Antibodies (Basel) 2020; 9 (04) 67
9 Reis ES, Mastellos DC, Hajishengallis G, Lambris JD. New insights into the immune functions of complement. Nat Rev Immunol 2019; 19 (08) 503-516
10 Nozaki M, Raisler BJ, Sakurai E. et al. Drusen complement components C3a and C5a promote choroidal neovascularization. Proc Natl Acad Sci U S A 2006; 103 (07) 2328-2333
11 Langer HF, Chung KJ, Orlova VV. et al. Complement-mediated inhibition of neovascularization reveals a point of convergence between innate immunity and angiogenesis. Blood 2010; 116 (22) 4395-4403
12 Del Conde I, Crúz MA, Zhang H, López JA, Afshar-Kharghan V. Platelet activation leads to activation and propagation of the complement system. J Exp Med 2005; 201 (06) 871-879
13 Subramaniam S, Jurk K, Hobohm L. et al. Distinct contributions of complement factors to platelet activation and fibrin formation in venous thrombus development. Blood 2017; 129 (16) 2291-2302
14 Nording H, Baron L, Haberthür D. et al. The C5a/C5a receptor 1 axis controls tissue neovascularization through CXCL4 release from platelets. Nat Commun 2021; 12 (01) 3352
15 Gawaz M, Langer H, May AE. Platelets in inflammation and atherogenesis. J Clin Invest 2005; 115 (12) 3378-3384
16 Schleicher RI, Reichenbach F, Kraft P. et al. Platelets induce apoptosis via membrane-bound FasL. Blood 2015; 126 (12) 1483-1493
17 Kraft P, Schleicher R, Olbrich M. et al. Platelet derived FasL contributes to apoptosis in stroke. Thromb Haemost 2016; 116 (05) 998-1000
18 Gaertner F, Ahmad Z, Rosenberger G. et al. Migrating platelets are mechano-scavengers that collect and bundle bacteria. Cell 2017; 171 (06) 1368-1382.e23
19 Verschoor A, Neuenhahn M, Navarini AA. et al. A platelet-mediated system for shuttling blood-borne bacteria to CD8α+ dendritic cells depends on glycoprotein GPIb and complement C3. Nat Immunol 2011; 12 (12) 1194-1201
20 Langer HF, Chavakis T. Leukocyte-endothelial interactions in inflammation. J Cell Mol Med 2009; 13 (07) 1211-1220
21 Kapur R, Semple JW. Platelet functions beyond hemostasis. In: Molecular and Cellular Biology of Platelet Formation. Cham: Springer International Publishing; 2017: 221-237
22 Langer HF, Choi EY, Zhou H. et al. Platelets contribute to the pathogenesis of experimental autoimmune encephalomyelitis. Circ Res 2012; 110 (09) 1202-1210
23 Huo Y, Schober A, Forlow SB. et al. Circulating activated platelets exacerbate atherosclerosis in mice deficient in apolipoprotein E. Nat Med 2003; 9 (01) 61-67
24 Massberg S, Gawaz M, Grüner S. et al. A crucial role of glycoprotein VI for platelet recruitment to the injured arterial wall in vivo. J Exp Med 2003; 197 (01) 41-49
25 Sauter RJ, Sauter M, Reis ES. et al. Functional relevance of the anaphylatoxin receptor C3aR for platelet function and arterial thrombus formation marks an intersection point between innate immunity and thrombosis. Circulation 2018; 138 (16) 1720-1735
26 Sauter RJ, Sauter M, Obrich M. et al. Anaphylatoxin receptor C3aR contributes to platelet function, thrombus formation and in vivo haemostasis. Thromb Haemost 2019; 119 (01) 179-182
27 Patzelt J, Mueller KAL, Breuning S. et al. Expression of anaphylatoxin receptors on platelets in patients with coronary heart disease. Atherosclerosis 2015; 238 (02) 289-295
28 Klement GL, Yip TT, Cassiola F. et al. Platelets actively sequester angiogenesis regulators. Blood 2009; 113 (12) 2835-2842
29 Keeling AN, Carroll TJ, McDermott MM. et al. Clinical correlates of size and number of collateral vessels in peripheral artery disease. Vasc Med 2012; 17 (04) 223-230
30 Martins Lima A, Martins Cavaco AC, Fraga-Silva RA, Eble JA, Stergiopulos N. From patients to platelets and back again: pharmacological approaches to glycoprotein VI, a thrilling antithrombotic target with minor bleeding risks. Thromb Haemost 2019; 119 (11) 1720-1739
31 Oksjoki R, Laine P, Helske S. et al. Receptors for the anaphylatoxins C3a and C5a are expressed in human atherosclerotic coronary plaques. Atherosclerosis 2007; 195 (01) 90-99
32 Nording H, Giesser A, Patzelt J. et al. Platelet bound oxLDL shows an inverse correlation with plasma anaphylatoxin C5a in patients with coronary artery disease. Platelets 2016; 27 (06) 593-597
33 Carvelli J, Demaria O, Vély F. et al; Explore COVID-19 IPH group, Explore COVID-19 Marseille Immunopole group. Association of COVID-19 inflammation with activation of the C5a-C5aR1 axis. Nature 2020; 588 (7836) 146-150
34 Aiello S, Gastoldi S, Galbusera M. et al. C5a and C5aR1 are key drivers of microvascular platelet aggregation in clinical entities spanning from aHUS to COVID-19. Blood Adv 2022; 6 (03) 866-881
35 Mastellos DC, Ricklin D, Lambris JD. Clinical promise of next-generation complement therapeutics. Nat Rev Drug Discov 2019; 18 (09) 707-729
36 Rother RP, Rollins SA, Mojcik CF, Brodsky RA, Bell L. Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria. Nat Biotechnol 2007; 25 (11) 1256-1264
37 Hillmen P, Szer J, Weitz I. et al. Pegcetacoplan versus eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med 2021; 384 (11) 1028-1037
38 Jayne DRW, Merkel PA, Schall TJ, Bekker P. ADVOCATE Study Group. Avacopan for the treatment of ANCA-associated vasculitis. N Engl J Med 2021; 384 (07) 599-609

Supplementary Material